Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

Delayed Quote. Delayed  - 09/28 10:00:00 pm
76.67 USD   -1.82%
09/28 ALNYLAM PHARMAC : Presents Clinical and Non-Clinical Data Demonstrat..
09/24 ALNYLAM PHARMAC : Reports Positive Initial Results from Ongoing Phas..
09/21 ALNYLAM PHARMAC : Reports Inducement Grant to New Chief Operating Of..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/22/2016 09/23/2016 09/26/2016 09/27/2016 09/28/2016 Date
77.09(c) 75.57(c) 76(c) 78.09(c) 76.67(c) Last
494 381 484 655 382 362 367 557 422 727 Volume
-0.90% -1.97% +0.57% +2.75% -1.82% Change
More quotes
Financials ($)
Sales 2016 39,2 M
EBIT 2016 -416 M
Net income 2016 -407 M
Finance 2016 645 M
Yield 2016 -
Sales 2017 60,0 M
EBIT 2017 -457 M
Net income 2017 -447 M
Finance 2017 573 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 151x
EV / Sales2017 100x
Capitalization 6 573 M
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which discovery, development and commercialization of RNAi therapeutics.It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.The... 
Sector
Biotechnology & Medical Research
Calendar
09/28 | 07:35pmPresentation
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
09/28 ALNYLAM PHARMACEUTICALS : Presents Clinical and Non-Clinical Data Demonstrating ..
09/24 ALNYLAM PHARMACEUTICALS : Reports Positive Initial Results from Ongoing Phase 1/..
09/21 ALNYLAM PHARMACEUTICALS, INC. : Reports Inducement Grant to New Chief Operating ..
09/20 ALNYLAM PHARMACEUTICALS : to Expand Global Footprint with New European Office in..
09/19 ALNYLAM PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Chan..
09/19 ALNYLAM PHARMACEUTICALS : Expands and Strengthens Management Team as it Plans fo..
09/07 ALNYLAM PHARMACEUTICALS : Reports Positive Interim Results from Ongoing Phase 1 ..
09/06 ALNYLAM PHARMACEUTICALS : to Webcast Presentations at Upcoming September Investo..
08/29 ALNYLAM PHARMACEUTICALS : Research Reports Initiation on Biotech Stocks -- Hemis..
08/25 ALNYLAM PHARMACEUTICALS : Patent Issued for Stable Non-Aggregating Nucleic Acid ..
More news
Sector news : Biotechnology & Medical Research - NEC
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
09/07 BENITEC BIOPHARMA : So What's Changed?
08/30 Prothena Builds Case For Amyloidosis Valuation
08/05 Alnylam Pharmaceuticals, Inc. 2016 Q2 - Results - Earnings Call Slides
08/05 Alnylam Pharmaceuticals (ALNY) John M. Maraganore on Q2 2016 Results - Earnin..
08/04 Alnylam Pharmaceuticals beats by $0.19, beats on revenue
Advertisement
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEU...
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 119 $
Spread / Average Target 55%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John M. Maraganore Chief Executive Officer & Director
Barry E. Greene President
Michael W. Bonney Chairman
Yvonne Greenstreet Chief Operating Officer & Executive Vice President
David-Alexandre Gros Chief Financial Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICAL..-18.56%6 573
INCYTE CORPORATION-14.06%17 522
CELLTRION, INC.--.--%11 533
LONZA GROUP AG12.32%10 064
QUINTILES TRANSNATIONA..15.89%9 472
SEATTLE GENETICS, INC.23.28%7 775
More Results